Pediatric lymphoma: Metabolic tumor burden as a quantitative index for treatment response evaluation

Annals of Nuclear Medicine

Volumn 26, Issue 1, 2012, Pages 58-66

  Sharma, Punit ^a   Gupta, Arun ^a   Patel, Chetan ^a   Bakhshi, Sameer ^b   Malhotra, Arun ^a   Kumar, Rakesh ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

Metabolic tumor burden (MTB); Pediatric lymphoma; PET CT; Treatment response

Indexed keywords

FLUORODEOXYGLUCOSE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW BIOPSY; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LYMPHOMA; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LYMPHOMA; MALE; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84858707749     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-011-0539-2     Document Type: Article

References (30)

1. Sandland JT, Downing JR, Crist WM. Non Hodgkin's lymphoma in childhood. N Eng J Med. 1996;334:1238-48.
2. Kumar R, Maillard I, Schuster SJ, Alavi A. The utility of FDG-PET imaging in management of patients with Hodgkin's and Non Hodgkin's lymphomas. Radiol Clin North Am. 2004;42:1083-100. (Pubitemid 39361461)
3. Murphy SB, Fairclough DL, Hutchinson RE, Berard CW. Non Hodgkin's lymphomas of childhood: an analysis of histology, staging and response to treatment of 338 cases at a single institution. J Clin Oncol. 1989;7:186-93. (Pubitemid 19048451)
4. Mauch PM, Weinstein H, Botnick L, Belli J, Cassady JR. An evaluation of long term survival and treatment complications in children with Hodgkin's disease. Cancer. 1988;51:925-32.
5. Schwartz CL. The management of Hodgkin's disease in the young child. Curr Opin Pediatr. 2003;15:1-2.
6. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
7. Geus-Oei LF, van der Heijden HFM, Visser EP, Hermsen R, van Hoorn BA, Timmer-Bonte JN, et al. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. J Nucl Med. 2007;48:1592-8. (Pubitemid 47572705)
8. de Wit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld DK. Whole body positron emission tomography for diagnosis of residual mass in patients with lymphoma. Ann Oncol. 1997;8:57-60.
9. Kumar R. Assessment of therapy response in malignant tumors with 18F-FLT. Eur J Nucl Med Mol Imaging. 2007;34:1334-8. (Pubitemid 47312594)
10. Ciernik IF, Dizendorf E, Baumert BG. Radiation treatment planning with an integrated positron emission and computer tomography (PET-CT): a feasibility study. Int J Radiat Oncol Biol Phys. 2003;57:853-63. (Pubitemid 37194314)
11. Amthauer H, Furth C, Denecke T, Hundsdoerfer P, Voelker T, Seeger K, et al. FDG-PET in 10 children with non-Hodgkin's lymphoma: initial experience in staging and follow up. Klin Padiatr. 2005;217:327-33. (Pubitemid 41746114)
12. Riad R, Omar W, Kotb M, Hafez M, Sidhom I, Zamzam M, et al. Role of PET-CT in malignant pediatric lymphoma. Eur J Nucl Med Mol Imaging. 2010;37:319-29.
13. Miller E, Metser U, Avrahami G, Dvir R, Valdman D, Sira LB, et al. Role of 18F-FDG PET-CT in staging and follow-up of lymphoma in pediatric and young adult patients. J Comput Assist Tomogr. 2006;30:689-94. (Pubitemid 44091528)
14. Benz MR, Evilevitch V, Allen-Auerbach MS, Eilber FC, Phelps ME, Czernin J, et al. Treatment monitoring by 18F-FDG PET-CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med. 2008;49:1038-46. (Pubitemid 351948010)
15. Graves EE, Quon A, Loo BW. RT-Image: an open-source tool for investigating PET in radiation oncology. Technol cancer Res Treat. 2007;6:111-21. (Pubitemid 46668718)
16. Surbone A, Longo DL, DeVita VT Jr, Ihde DC, Duffey PL, Jaffe ES, et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. J Clin Oncol. 1988;6:1832-7. (Pubitemid 19089065)
17. Radford JA, Cowan RA, Flanagan M, Dunn G, Crowther D, Johnson RJ, et al. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J Clin Oncol. 1988;6:940-6.
18. Jochelson M, Mauch P, Balikian J, Rosenthal D, Canellos G, et al. The significance of the residual mediastinal mass in treated Hodgkin's disease. J Clin Oncol. 1985;3:637-40. (Pubitemid 15119234)
19. Stewart FM, Williamson BR, Innes DJ, Hess CE. Residual tumor masses following treatment for advanced histiocytic lymphoma. Diagnostic and therapeutic implications. Cancer. 1985;55:620-3. (Pubitemid 15156033)
20. Hermann S, Wormann D, Pixberg M, Hunold A, Heindel W, Jürgens H, et al. Staging in childhood lymphoma: difference between FDG PET and CT. Nuklearmedizin. 2005;44:1-7.
21. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica. 2000;85:613-8. (Pubitemid 30450941)
22. Jerusalem G, Hustinx R, Beguin Y, Fillet G. Evaluation of therapy for lymphoma. Semin Nucl Med. 2005;35:186-96. (Pubitemid 41138137)
23. Kumar R, Maillard I, Schuster SJ, Alavi A. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Radiol Clin North Am. 2004;42:1083-100. (Pubitemid 39361461)
24. Berkowitz A, Basu S, Srinivas S, Sankaran S, Schuster S, Alavi A. Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET. Nucl Med Commun. 2008;29: 521-6. (Pubitemid 351643419)
25. Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J, et al. Early 18-F-FDG PET for prediction of prognosis in patients with patients with diffuse large cell lymphoma: SUV based assessment versus visual analysis. J Nucl Med. 2007;48:1626-32. (Pubitemid 47572710)
26. Alavi A, Newberg AB, Souder E, Berlin JA. Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators. J Nucl Med. 1993;34:1681-7. (Pubitemid 23295377)
27. Bural GG, Torigian DA, Chamroonrat W, Alkhawaldeh K, Houseni M, El-Haddad G, et al. Quantitative assessment of the atherosclerotic burden of the aorta by combined FDG-PET and CT image analysis: a new concept. Nucl Med Biol. 2006;33: 1037-43. (Pubitemid 44791952)
28. Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2:159-71.
29. Lee P, Weerasuriya DK, Lavori PW, Quon A, Hara W, Maxim PG, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiation Oncology Biol Phys. 2007;2:328-33. (Pubitemid 47380105)
30. La TH, Filion EJ, Turnbull BB, Chu JN, Lee P, Nguyen K, et al. Metabolic tumor volume predicts for recurrence and death in head and neck cancer. Int J Radiation Oncology Biol Phys. 2009;5:1335-41.